

18-06-2001

GE 000000002

AKJH

7

Claims

1. Use of antiepileptic and anticonvulsive effective substances selected from the group comprising 1) barbituric acid, 2) hydantoin, 3) pyrimidine, 4) oxazolidinedione, 5) indandione, 6) succinimide, 7) iminostilben, 8) butamsultham, 9) valproic acid and salts of valproic acid, 10) aminoindandions, 11) acethylcarbamate, 12) beta-chlorpropionic acid, 13) tетronic acid, 14) sulfonamides, 15) fructose sulfamates, 16) pyrrolidine, 17) acetamides, 18) propylene glycols, 19) nipecotic acid, 20) triasines, 21) gamma-aminobutyric acid, 22) thiazoles, 23) selenazoles, 24) pirazoles, 25) izatine, 26) diphenylsulphone, 27) ethylselenazolidindione, 28) benzimidazolin-2tione, 29) dioxolanes, 30) azetidines, 31) triazoles, 32) acetamides, 33) imidazoles and their pharmaceutically acceptable derivatives for the manufacture of drugs for the treatment of all types of bronchial asthma and related diseases and syndromes.
2. Use of the substances according to claim 1, wherein as iminostilben derivative carbamazepine and oxcarbazepine is selected.
3. Use of the substances according to claim 1, wherein as hydantoin derivative fosphenytoin is selected.
4. Use of the substances according to claim 1 , wherein as triasine derivative lamotrigine is selected.
5. Use of the substances according to claim 1,

AMENDED SHEET

wherein as propylen glycol derivative felbamate is selected.

6. Use of the substances according to claim 1,
wherein as nipecotic acid derivative tiagabine is selected.
7. Use of the substances according to claim 1,
wherein as sulfonamide derivative zonisamide is selected.
8. Use of the substances according to claim 1,
wherein as fructose sulfamate derivative topiramate is selected.
9. Use of the substances according to claim 1,
wherein valproic acid is administered in the form of a pharmaceutically acceptable salt or ester.
10. Use of the substances according to claim 1,
wherein as pyrrolidine derivative levetiracetam is selected.
11. Use of the substances according to claim 1,
wherein as butansultham derivative sultiam is selected.
12. Use of the substances according to claim 1,
wherein as tetronic acid derivative losigamone is selected.
13. Use of the substances according to claim 1,
wherein as gamma-aminobutyric acid derivative gabapentine or vigabatrin and progabide is selected.

18-06-2001

3

14. Use of the substances according to claim 1, wherein as succinimide derivative aethosuximide is selected.
15. Use of the substances according to claim 1, wherein as pyrimidine derivative hexamidin and primidone is selected.
16. Use of the substances according to claim 1, wherein as oxazolidinedione derivative trimethindione is selected.
17. Use of the substances according to claim 1, wherein as butamsultham derivative sultiam is selected.
18. Use of the substances according to claim 1, wherein as aminoindandion derivative methindione is selected.
19. Use of the substances according to claim 1, wherein as acethylcarbamate derivative phenacemide is selected.
20. Use of the substances according to claim 1, wherein as beta-chlorpropionic acid derivative beclamide is selected.
21. Use of the substances according to claim 1, wherein as acetamide derivative remacemide hydrochloride and milacemide is selected.
22. Use of the substances according to claim 1, wherein as thiazole derivative ralitoline is selected.

AMENDED SHEET

18-06-2001

GE 000000002

4

ARKY

23. Use of the substances according to claim 1, wherein as dioxolane derivative stiripentol is selected.
24. Use of the substances according to claim 1, wherein as azetidine derivative dezinamide is selected.
25. Use of the substances according to claim 1, wherein as triazole derivative loreclezole is selected.
26. Use of the substances according to claim 1, wherein as acethylcarbamate derivative phenacemide is selected.
27. Use of antiepileptic and anticonvulsive effective substances selected from the group comprising carbamazepine, oxcarbazepine, fosphenytoin, lamotrigine, felbamate, tiagabine, zonisamide, topiramate, valproic acid, levetiracetam, sultiam, losigamone, gabapentine, vigabatrin, progabide, aethosuximide, hexamidin, primidone, methindione, trimethindione, sultiam, phenacemide, beclamide, remacimide, hydrochloride, ralitoline, stiripentol, dezinamide, loreclezole, milademide, nafimidone and their pharmaceutically acceptable derivatives for the manufacture of drugs for the treatment of all types of bronchial asthma and related diseases and syndromes.
28. Use of the substances according to one of claims 1 to 27, wherein the related diseases and syndromes are asthmatic and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes.

AMENDED SHEET